Special Issue "Neuroendocrine Tumors"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2011)
Dr. med. Volker Fendrich
Department of Surgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany
Fax: +49 06421 - 5862105
Interests: pancreatic cancer; neuroendocrine tumors; mouse models of cancer; chemoprevention
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are uncommon but clinically challenging and fascinating tumors. GEP-NETs present as either functional or as non-functional tumors. Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, like gastrinomas with a Zollinger-Ellison-Syndrome or carcinoid syndrome in patients with neuroendocrine tumors (NET) of the ileum. Non-functional tumors do not secrete a hormone resulting in a clinical syndrome. The natural course of GEP-NETs is highly variable. Small, benign neoplasms such as 90% of all insulinomas or gastric endocrine tumors type 1 are readily curable by surgical resection; however, most other GEP-NETs have a much less favorable prognosis. Patients with completely resected tumors generally have a good prognosis, and an aggressive surgical
approach in patients with advanced disease may also prolong survival. This special issue focuses on the current standards of management of gastric endocrine tumors, NETs of the pancreas (PNET) and NETs of the ileum. Although the evidence level is low in many instances due to the lack of randomized controlled trials, important treatment recommendations can be given.
Dr. Volker Fendrich
- neuroendocrine gastrointestinal tumor
- neuroendocrine tumors of the ileum
- neuroendocrine tumors of the pancreas
- surgical therapy